Fluvoxamine

Fluvoxamine, a strong CYP1A2 inhibitor, increases alosetron AUC approximately 6-fold and prolongs half-life approximately 3-fold, resulting in increased exposure.

Fluvoxamine, a strong CYP1A2 inhibitor, increased alosetron AUC approximately 6-fold and prolonged half-life approximately 3-fold. Concomitant use is contraindicated.

Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine.

Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine to avoid vasospasm risk.

Serious, sometimes fatal reactions reported when used concomitantly with MAO inhibitors.

Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.

Strong CYP1A2 inhibitor that increases ramelteon AUC approximately 190-fold and Cmax approximately 70-fold; should not be used in combination.

Increases thioridazine and active metabolites (mesoridazine, sulforidazine) 3-fold. Should not be coadministered.

Concomitant use is contraindicated. Results in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.

Strong CYP1A2 inhibitor causing significantly decreased blood pressure, increased drowsiness, and psychomotor impairment when combined with tizanidine.

Strong CYP1A2 inhibitor; concomitant use contraindicated due to significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.

Strong CYP2C19 inhibitor that increases aficamten exposure, potentially increasing risk of heart failure due to systolic dysfunction. Dose reduction required.

SSRI that inhibits P450 2D6 and P450 1A2, both involved in clomipramine metabolism, may increase plasma levels.

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

Strong CYP1A2 inhibitor reduces ropivacaine plasma clearance by 70%, leading to increased ropivacaine levels.

Inhibits hepatic enzymes (CYP3A and 2C19), leading to increased and prolonged sedation.

Potent CYP1A2 inhibitor increased duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and half-life approximately 3-fold. Should be avoided.

Potent CYP1A2 inhibitor increases duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and t1/2 approximately 3-fold.

Potent CYP1A2 inhibitor increases duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and t1/2 approximately 3-fold.

CYP1A2 inhibitor that increases lidocaine plasma AUC by 71% and Cmax by 22%, decreases clearance by 41%-60%, and prolongs half-life by one hour.

SSRI and CYP inhibitor that increases methadone plasma concentration, resulting in increased opioid effects and potential fatal overdose.

SSRI and CYP2C19/CYP3A4 inhibitor that increases methadone plasma concentration, resulting in increased opioid effects and risk of fatal overdose.

Strong CYP1A2 inhibitor significantly increases pirfenidone exposure. Concomitant use is not recommended; discontinue fluvoxamine prior to pirfenidone administration or reduce pirfenidone to 267 mg three times daily.

Strong CYP1A2 inhibitor that increased pomalidomide Cmax by 24% and AUC by 125%, increasing risk of exposure-related toxicities. Avoid concomitant use; if unavoidable, reduce pomalidomide dose.

CYP3A4 and CYP1A2 inhibitor that increases roflumilast systemic exposure and may result in increased adverse reactions.

Strong CYP1A2 inhibitor reduced plasma clearance of ropivacaine by 70%, leading to increased ropivacaine plasma levels.

Strong CYP1A2 inhibitor that increases tasimelteon exposure, potentially causing a large increase in drug levels and greater risk of adverse reactions.

Inhibitor of CYP2C9 and CYP1A2 that increases warfarin effect and INR; requires close INR monitoring

CYP2C9 and CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Moderate CYP3A inhibitor may increase alprazolam concentrations; avoid use or consider dose reduction.

Weak CYP3A inhibitor may increase alprazolam concentrations. Avoid use and consider dose reduction.

CYP1A2 inhibitor may increase anagrelide exposure; monitor for cardiovascular events and titrate dose accordingly.

CYP1A2 inhibitor may increase anagrelide exposure; monitor for cardiovascular events and adjust dose.

Strong CYP1A2 inhibitor that increases asenapine exposure. Full therapeutic doses expected to cause greater increase in asenapine exposure.

Strong CYP1A2 inhibitor that increases asenapine exposure. Full therapeutic dose expected to cause greater increase in asenapine exposure.

CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.

CYP2C19 inhibitor that could result in increased carisoprodol exposure and decreased meprobamate exposure; full pharmacological impact unknown.

Strong CYP2C19 inhibitor that may increase exposure to N-desmethylclobazam active metabolite, increasing risk of dose-related adverse reactions.

Weakness, hyperreflexia, and incoordination may occur rarely with coadministration of selective serotonin reuptake inhibitors.

Significant CYP3A inhibitor; estazolam should be used with caution and appropriate dosage reduction may be needed.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

CYP1A2 inhibitor that decreases mexiletine clearance by 38%, requiring dose titration.

CYP1A2 inhibitor decreases olanzapine clearance, increasing Cmax by 54% (female nonsmokers) to 77% (male smokers); lower olanzapine doses recommended.

May increase olanzapine levels; lower dose of olanzapine component should be considered.

Fluvoxamine decreases olanzapine clearance, increasing olanzapine Cmax by 54-77% and AUC by 52-108%. Lower olanzapine doses should be considered.

Strong CYP1A2 inhibitor that may increase exposure to pentoxifylline.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

CYP1A2 and CYP2C19 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Data from clinical studies of similar benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.

Moderate CYP3A4 inhibitor. Dose adjustment recommended with concomitant use.

In vitro studies suggest fluvoxamine inhibits the hydroxylation of bupropion; no clinical studies performed to evaluate this finding.